<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525301</url>
  </required_header>
  <id_info>
    <org_study_id>RT-15-02 SHARON BRAIN</org_study_id>
    <nct_id>NCT03525301</nct_id>
  </id_info>
  <brief_title>Short Course Radiation Therapy in Palliative Treatment of Brain Metastases</brief_title>
  <official_title>SHort Course Accelerated RadiatiON Therapy (SHARON) in Palliative Treatment of Brain Metastases: an Interventional, Randomised, Multicentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to assess efficacy of a short course radiation treatment in patients with
      symptomatic brain metastases from solid tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment for brain metastases (3000 cGy in 10 daily fractions of 300 cGy each) is
      compared with experimental treatment (1800 cGy in 4 fractions of 450 cGy twice a day) to
      demonstrate non-inferiority of this scheme
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Anticipated">November 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 8, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of palliation using the short course scheme compared with the standard scheme</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction of initial symptoms after radiotherapy, assessed with Likert scale (weakness, motor disorders, cognitive impairment, personality changes, loss of balance, seizures, changes in speech, vision, hearing, memory problems, nausea or vomiting are evaluated as none-mild-moderate-severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity in the two treatment groups</measure>
    <time_frame>3 months</time_frame>
    <description>Incidence of treatment-related acute adverse events in the two arms of the study registered using Cooperative Group Common Toxicity Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity in the two treatment groups</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of treatment-related late adverse events in the two arms of the study registered using RTOG/EORTC Late Radiation Morbility Scoring Schema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) assessment in the two groups</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in QoL after the treatment assessed using European Organization for Research and Treatment of Cancer (EORTC) questionnaire C15-PAL (a specific questionnaire from EORTC developed to assess the quality of life of palliative cancer care patients)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Brain Metastases</condition>
  <condition>Radiotherapy</condition>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this group are treated with 3000 cGy in 10 daily fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>short course treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard treatment</intervention_name>
    <description>3000 cGy in 10 daily fractions</description>
    <arm_group_label>standard treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>short course treatment</intervention_name>
    <description>1800 cGy in 4 fractions administered twice a day</description>
    <arm_group_label>short course treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symptomatic brain metastases from solid tumors

          -  age &gt; 18 years

          -  ECOG performance status 0-3

          -  no changes in supportive care in the week before radiotherapy

        Exclusion Criteria:

          -  pregnancy

          -  previous irradiation of the same region
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessio G Morganti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine-DIMES, Unversity of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessio G Morganti, MD</last_name>
    <phone>0512143564</phone>
    <phone_ext>+39</phone_ext>
    <email>alessio.morganti2@unibo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessio G Morganti, MD</last_name>
      <phone>0512143564</phone>
      <phone_ext>+39</phone_ext>
      <email>alessio.morganti2@unibo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Alessio Giuseppe Morganti</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Short Course Radiotherapy</keyword>
  <keyword>Symptomatic brain metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

